Literature DB >> 809484

Serotyping of Pseudomonas aeruginosa isolates from patients with cystic fibrosis of the pancreas.

C H Zierdt, R L Williams.   

Abstract

Pseudomonas aeruginosa isolates (173) from 144 patients with cystic fibrosis (CF) of the pancreas in seven hospitals were serotyped with the agglutination systems of Homma (1974) and Fisher et al. (1969). The two systems were complementary. Strains from CF patients were much less likely to furnish a stable type on repetitive typing tests than strains from other patients. This was related to the frequent occurrence of mucoid P. aeruginosa strains. The 173 strains were divided among 11 Homma serotypes. A single Homma type (type 8) capable of mucoid growth comprised 104 (60%) CF strains. Eight serotypes were detected in 77 strains from 48 CF patients in one hospital; three strains were detected in one hospital CF unit; and two strains were detected in each of five hospital CF units. The CF serotype comprised from 50 to 93% of CF strians inthe seven hospitals. These P. aeruginosa strains dissociated in vivo as judged by mucoid and nonmucoid colonies on primary culture plates and continued to dissociate during subcultures. Both colony type were the same serotype. The tendency to regard colonial phenotypes (mucoid, nonmucoid, rough) as separate strians was erroneous. Repetitive typing with the two systems gave better results than a single system. The mucoid P. aeruginosa strain is probably spread from patient to patient, rather than acquiring its mucoid characteristic de novo in the CF patient. It is not known why the mucoid CF strain has a peculiar predilection for CF patients, nor why it generally loses the quality in culture but retains it indefinitely in the patient.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 809484      PMCID: PMC275175          DOI: 10.1128/jcm.1.6.521-526.1975

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  13 in total

1.  ENCAPSULATED PSEUDOMONAS AERUGINOSA (PSEUDOMONAS AERUGINOSA MUCOSUS) STRAINS.

Authors:  E T CETIN; K TOERECI; O ANG
Journal:  J Bacteriol       Date:  1965-05       Impact factor: 3.490

2.  Increasing incidence of encapsulated Pseudomonas aeruginosa strains.

Authors:  H R Elston; K C Hoffman
Journal:  Am J Clin Pathol       Date:  1967-11       Impact factor: 2.493

3.  New immunotype schema for Pseudomonas aeruginosa based on protective antigens.

Authors:  M W Fisher; H B Devlin; F J Gnabasik
Journal:  J Bacteriol       Date:  1969-05       Impact factor: 3.490

4.  Serological typing of Pseudomonas aeruginosa and several points to be considered.

Authors:  J Y Homma
Journal:  Jpn J Exp Med       Date:  1974-02

5.  Changes in serotype of Pseudomonas aeruginosa.

Authors:  J Y Homma; H Shionoya; H Yamada; M Enomoto; K Miyao
Journal:  Jpn J Exp Med       Date:  1972-04

6.  the significance of pattern variations in pyocine typing of Pseudomonas aeruginosa.

Authors:  P Chadwick
Journal:  Can J Microbiol       Date:  1972-07       Impact factor: 2.419

7.  Slime production by Pseudomonas aeruginosa. I. Conditions for slime production by the cellophane plate method.

Authors:  S Goto; S Enomoto; Y Takahashi; R Motomatsu
Journal:  Jpn J Microbiol       Date:  1971-07

8.  Incidence of mucoid Pseudomonas aeruginosa from clinical sources.

Authors:  R G Doggett
Journal:  Appl Microbiol       Date:  1969-11

9.  Dissociation in Pseudomonas aeruginosa.

Authors:  C H Zierdt; P J Schmidt
Journal:  J Bacteriol       Date:  1964-05       Impact factor: 3.490

10.  Pyocin typing of Pseudomonas aeruginosa: a simplified method.

Authors:  L F Jones; J P Zakanycz; E T Thomas; J J Farmer
Journal:  Appl Microbiol       Date:  1974-02
View more
  18 in total

1.  Colonial dissociation and susceptibility to phagocytosis of Pseudomonas aeruginosa grown in a chamber implant model in mice.

Authors:  N M Kelly; J L Battershill; S Kuo; J P Arbuthnott; R E Hancock
Journal:  Infect Immun       Date:  1987-11       Impact factor: 3.441

2.  R-factor inheritance and plasmid content in mucoid Pseudomonas aeruginosa.

Authors:  S M Markowitz; F L Macrina; P V Phibbs
Journal:  Infect Immun       Date:  1978-11       Impact factor: 3.441

3.  Proteins of the cystic fibrosis respiratory tract. Fragmented immunoglobulin G opsonic antibody causing defective opsonophagocytosis.

Authors:  R B Fick; G P Naegel; S U Squier; R E Wood; J B Gee; H Y Reynolds
Journal:  J Clin Invest       Date:  1984-07       Impact factor: 14.808

4.  Pseudomonas aeruginosa isolates from patients with cystic fibrosis: a class of serum-sensitive, nontypable strains deficient in lipopolysaccharide O side chains.

Authors:  R E Hancock; L M Mutharia; L Chan; R P Darveau; D P Speert; G B Pier
Journal:  Infect Immun       Date:  1983-10       Impact factor: 3.441

5.  Role of alginate in infection with mucoid Pseudomonas aeruginosa in cystic fibrosis.

Authors:  S S Pedersen; N Høiby; F Espersen; C Koch
Journal:  Thorax       Date:  1992-01       Impact factor: 9.139

6.  Active immunization with lipopolysaccharide Pseudomonas antigen for chronic Pseudomonas bronchopneumonia in guinea pigs.

Authors:  J E Pennington; W F Hickey; L L Blackwood; M A Arnaut
Journal:  J Clin Invest       Date:  1981-11       Impact factor: 14.808

7.  Cystic fibrosis pseudomonas opsonins. Inhibitory nature in an in vitro phagocytic assay.

Authors:  R B Fick; G P Naegel; R A Matthay; H Y Reynolds
Journal:  J Clin Invest       Date:  1981-10       Impact factor: 14.808

8.  Phenotypic differences among clinically isolated mucoid Pseudomonas aeruginosa strains.

Authors:  B K Pugashetti; H M Metzger; L Vadas; D S Feingold
Journal:  J Clin Microbiol       Date:  1982-10       Impact factor: 5.948

9.  Pseudomonas aeruginosa cross-colonization and persistence in patients with cystic fibrosis. Use of a DNA probe.

Authors:  C Wolz; G Kiosz; J W Ogle; M L Vasil; U Schaad; K Botzenhart; G Döring
Journal:  Epidemiol Infect       Date:  1989-04       Impact factor: 2.451

10.  Pseudomonas aeruginosa population structure revisited.

Authors:  Jean-Paul Pirnay; Florence Bilocq; Bruno Pot; Pierre Cornelis; Martin Zizi; Johan Van Eldere; Pieter Deschaght; Mario Vaneechoutte; Serge Jennes; Tyrone Pitt; Daniel De Vos
Journal:  PLoS One       Date:  2009-11-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.